Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 277-288

  Redondo Muller M A ^a   Stevanovic Walker, M ^a   Barker, S ^a   Puddefoot, J R ^a   Vinson, G P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CASPASE 3; CASPASE 7; LOSARTAN; RECOMBINANT ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER LOCALIZATION; CELL COUNT; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; FEMALE; HOLLOW FIBER; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; TUMOR REGRESSION; XENOGRAFT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOOD PRESSURE DETERMINATION; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASES; CELL SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LOSARTAN; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; VASOCONSTRICTOR AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 41349089063     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0068     Document Type: Article

References (61)

1. Arrieta O, Guevara P, Escobar E, Garcia-Navarrete R, Pineda B & Sotelo J 2005 Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. British Journal of Cancer 92 1247-1252.
2. Barker S, Marchant W, Ho MM, Puddefoot JR, Hinson JP, Clark AJL & Vinson GP 1993 A monoclonal antibody to a conserved sequence in the extracellular domain recognizes the angiotensin II AT1 receptor in mammalian tissues. Journal of Molecular Endocrinology 11 241-245.
3. Barker S, Kapas S, Corder R & Clark AJ 1996 Adrenomedullin acts via stimulation of cyclic amp and not via calcium signalling in vascular cells in culture. Journal of Human Hypertension 10 421-423.
4. Berry C, Touyz R, Dominiczak AF, Webb RC & Johns DG 2001 Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. American Journal of Physiology. Heart and Circulatory Physiology 281 H2337-H2365.
5. Boutinaud M, Guinard-Flament J & Jammes H 2004 The number and activity of mammary epithelial cells, determining factors for milk production. Reproduction, Nutrition, Development 44 499-508.
6. Bridges EM, Bibby MC & Burchill SA 2006 The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors. Journal of Pediatrics 149 103-111.
7. Decaillot FM, Befort K, Filliol D, Yue S, Walker P & Kieffer BL 2003 Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nature Structural Biology 10 629-636.
8. Diep QN, Li JS & Schiffrin EL 1999 In vivo study of AT(1) and AT(2) angiotensin receptors in apoptosis in rat blood vessels. Hypertension 34 617-624.
9. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T et al. 2003 Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. Journal of Clinical Investigation 112 67-75.
10. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Norgaard M, McLaughlin JK & Friis S 2006 A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Research and Treatment 97 231-236.
11. Fujimoto Y, Sasaki T, Tsuchida A & Chayama K 2001 Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Letters 495 197-200.
12. Fujita M, Hayashi I, Yamashina S, Itoman M & Majima M 2002 Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochemical and Biophysical Research Communications 294 441-447.
13. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M & Majima M 2005 Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26 271-279.
14. de Gasparo M 2002 AT(1) and AT(2) angiotensin II receptors: key features. Drugs 62 1-10.
15. de Gasparo M, Catt KJ, Inagami T, Wright JW & Unger T 2000 International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacological Reviews 52 415-472.
16. Gonzalez-Perez A, Ronquist G & Rodriguez LAG 2004 Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiology and Drug Safety 13 581-585.
17. Greco S, Elia MG, Muscella A, Storelli C & Marsigliante S 2002a AT1 angiotensin ii receptor mediates intracellular calcium mobilization in normal and cancerous breast cells in primary culture. Cell Calcium 32 1-10.
18. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C & Marsigliante S 2002b Activation of angiotensin II type I receptor promotes protein kinase C translocation and cell proliferation in human cultured breast epithelial cells. Journal of Endocrinology 174 205-214.
19. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, Manca C & Marsigliante S 2003 Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. Journal of Cellular Physiology 196 370-377.
20. Green KA & Streuli CH 2004 Apoptosis regulation in the mammary gland. Cellular and Molecular Life Sciences 61 1867-1883.
21. Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES & Devi LA 2007 Conformation state-sensitive antibodies to G-protein-coupled receptors. Journal of Biological Chemistry 282 5116-5124.
22. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK & Jonsson JR 1998 Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. British Journal of Cancer 77 880-883.
23. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malpais L & Grever MR 1995 In vivo cultivation of tumor cells in hollow fibers. Life Sciences 57 131-141.
24. Inwang ER, Puddefoot JR, Brown CL, Goode AW, Marsigliante S, Ho MM, Payne JG & Vinson GP 1997 Angiotensin II type 1 receptor expression in human breast tissues. British Journal of Cancer 75 1279-1283.
25. Kapas S, Hinson JP, Puddefoot JR, Ho MM & Vinson GP 1994 Internalization of the type-1 angiotensin-II receptor (AT1) is required for protein-kinase-C activation but not for inositol trisphosphate release in the angiotensin-II stimulated rat adrenal zona glomerulosa cell. Biochemical and Biophysical Research Communications 204 1292-1298.
26. Kaschina E & Unger T 2003 Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Pressure 12 70-88.
27. Kasukabe T, Okabe-Kado J, Kato N, Sassa T & Honma Y 2005 Effects of combined treatment with rapamycin and cotylenin a, a novel differentiation- inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Research 7 R1097-R1110.
28. Kivinen K, Kallajoki M & Taimen P 2005 Caspase-3 is required in the apoptotic disintegration of the nuclear matrix. Experimental Cell Research 311 62-73.
29. Lecat S, Bucher B, Mely Y & Galzi JL 2002 Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses. Journal of Biological Chemistry 277 42034-42048.
30. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL & Robertson JWK 1998 Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 179-184.
31. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL & Daling JR 2003 Relation between use of anti hypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98 1504-1513.
32. Meier CR, Derby LE, Jick SS & Jick H 2000 Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Archives of Internal Medicine 160 349-353.
33. Mi Q, Lantvit D, Reyes-Lim E, Chai H, Zhao W, Lee IS, Peraza-Sanchez S, Ngassapa O, Kardono LB, Riswan S et al. 2002 Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests. Journal of Natural Products 65 842-850.
34. Miyajima A, Asano T & Hayakawa M 2001 Captopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth factor-beta in murine renal cell cancer cells. Journal of Urology 165 616-620.
35. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T & Hayakawa M 2002 Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Research 62 4176-4179.
36. Mulrow PJ 1999 Angiotensin II and aldosterone regulation. Regulatory Peptides 80 27-32.
37. Muscella A, Greco S, Elia MG, Storelli C & Marsigliante S 2002 Angiotensin II stimulation of NA+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. Journal of Endocrinology 173 315-323.
38. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C, Masson M et al. 2004 Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. Journal of Biological Chemistry 279 28989-28997.
39. Ohashi H, Takagi H, Oh H, Suzuma K, Suzuma I, Miyamoto N, Uemura A, Watanabe D, Murakami T, Sugaya T et al. 2004 Phosphatidylinositol 3-kinase/Akt regulates angiotensin Ii-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circulation Research 94 785-793.
40. De Paepe B, Verstraeten VL, De Potter CR, Vakaet LA & Bullock GR 2001 Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochemistry and Cell Biology 116 247-254.
41. De Paepe B, Verstraeten VM, De Potter CR & Bullock GR 2002 Increased angiotensin II type-2 receptor density in hyperplasia, dcis and invasive carcinoma of the breast is paralleled with increased inos expression. Histochemistry and Cell Biology 117 13-19.
42. Prunet C, Lemaire-Ewing S, Menetrier F, Neel D & Lizard G 2005 Activation of caspase-3-dependent and -independent pathways during 7-ketocholesterol- and 7β-hydroxycholesterol-induced cell death: a morphological and biochemical study. Journal of Biochemical and Molecular Toxicology 19 311-326.
43. Puddefoot JR, Udeozo UKI, Barker S & Vinson GP 2006 The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocrine-Related Cancer 13 895-903.
44. Puett D, Li Y, Angelova K, Demars G, Meehan TP, Fanelli F & Narayan P 2005 Structure-function relationships of the luteinizing hormone receptor. Annals of the New York Academy of Sciences 1061 41-54.
45. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A & Sotelo J 2001 AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. British Journal of Cancer 85 1396-1399.
46. Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G & Svardsudd K 2004 Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 58 50-56.
47. Stoll M & Unger T 2001 Angiotensin and its AT2 receptor: new insights into an old system. Regulatory Peptides 99 175-182.
48. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S & Kikkawa F 2005 Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clinical Cancer Research 11 2686-2694.
49. Tahmasebi M, Puddefoot JR, Inwang ER, Goode AW, Carpenter R & Vinson GP 1998 Transcription of the prorenin gene in normal and diseased breast. European Journal of Cancer 34 1777-1782.
50. Tahmasebi M, Barker S, Puddefoot JR & Vinson GP 2006 Localisation of renin-angiotensin system (RAS) components in breast. British Journal of Cancer 95 67-74.
51. Takeda H & Kondo S 2001 Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. American Journal of Pathology 158 1633-1637.
52. Thomas MA, Fleissner G, Stohr M, Hauptfleisch S & Lemmer B 2004 Localization of components of the renin-angiotensin system in the suprachiasmatic nucleus of normotensive sprague-dawley rats: Part a. Angiotensin I/II, a light and electron microscopic study. Brain Research 1008 212-223.
53. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A & Kubota Y 2003 Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Molecular Cancer Therapeutics 2 1139-1147.
54. Uemura H, Nakaigawa N, Ishiguro H & Kubota Y 2005 Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Current Cancer Drug Targets 5 307-323.
55. Vinson GP, Ho MM, Puddefoot JR, Teja R & Barker S 1994 Internalisation of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. Journal of Endocrinology 141 R5-R9.
56. Vinson GP, Barker S, Puddefoot JR & Tahmasebi M 2007 The renin-angiotensin system in the breast. In Frontiers in Research of the Renin-Angiotensin System on Human Disease, Ed PS Leung. Springer Verlag: Berlin.
57. Volpert OV, Ward WF, Lingen MW, Chester L, Solt DB, Johnson MD, Molteni A, Polverini PJ & Bouck NP 1996 Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. Journal of Clinical Investigation 98 671-679.
58. Weidekamm C, Hauser P, Hansmann C, Schwarz C, Klingler H, Mayer G & Oberbauer R 2002 Effects of AT1 and AT2 receptor blockade on angiotensin II induced apoptosis of human renal proximal tubular epithelial cells. Wiener Klinische Wochenschrift 114 725-729.
59. Wiseman BS & Werb Z 2002 Stromal effects on mammary gland development and breast cancer. Science 296 1046-1049.
60. Yang X, Zhu MJ, Sreejayan N, Ren J & Du M 2005 Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-receptor pathway. Molecules and Cells 20 263-270.
61. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S & Fukui H 2002 Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. Journal of Hepatology 37 22-30.